CRF Announces TCT 2023 Late-breaking Clinical Trials

Annual Scientific Symposium will take place October 23-26 in San Francisco

September 6, 2023 — The Cardiovascular Research Foundation (CRF) has announced the TCT 2023 late-breaking clinical trials. TCT is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine. TCT, which will be held October 23-26, 2023 in San Francisco, California, at the Moscone Center, will be celebrating 35 years of leading the field.

For more than three decades, TCT has ignited innovation, education, and connection in interventional cardiology, with the purpose of improving the survival and quality of life of patients suffering from heart and vascular disease. Every year, TCT features cutting-edge research in interventional cardiovascular medicine that directly impacts patient care and how physicians treat heart disease.

In the fast-paced world of medical advancements, late-breaking trials are highly anticipated and offer clinicians the opportunity to learn about new interventions, drugs, techniques, or strategies that could potentially improve patient outcomes. The 12 studies selected for presentation at TCT examine the safety and effectiveness of minimally invasive techniques, pharmaceuticals, technologies, and devices that demonstrate potential to treat or prevent cardiovascular disease. Late-breaking trials will be presented during the main sessions and highlighted during press conferences scheduled for Tuesday, October 24, Wednesday, October 25, and Thursday, October 26.

PARTNER 3 Low-Risk

Five-Year Clinical and Echocardiographic Outcomes from The PARTNER 3 Low-Risk Randomized Trial

Martin B. Leon, MD

EVOLUT Low Risk

Four-Year Outcomes from the EVOLUT Low Risk Trial

Michael J. Reardon, MD

WATCH TAVR

Safety and Efficacy of Left Atrial Appendage Occlusion at the Time of Transcatheter Aortic Valve Replacement — The WATCH TAVR Trial

Samir R. Kapadia, MD

ALIGN-AR

Initial Outcomes of the JenaValve Trilogy Transcatheter Aortic Valve Replacement System in High-Risk Patients with Symptomatic Severe Native Aortic Regurgitation

Vinod H. Thourani, MD

LIFE-BTK

Primary Outcomes of the Esprit BTK Drug-Eluting Resorbable Scaffold for the Treatment of Infrapopliteal Lesions: The LIFE-BTK Randomized Controlled Trial

Ramon L. Varcoe, MD

AGENT IDE

Primary Outcomes of a Pivotal Multicenter Randomized Trial Comparing the AGENT Paclitaxel-Coated Balloon with Conventional Balloon Angioplasty for In-Stent Restenosis

Robert W. Yeh, MD

T-PASS

Less Than 1-month Dual Antiplatelet Therapy Followed by Ticagrelor Monotherapy after Coronary Drug-Eluting Stent Implantation for Acute Coronary Syndrome: The T-PASS Randomized Trial

Myeong-Ki Hong, MD

PICSO-AMI-I

Pressure-Controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Acute Myocardial Infarction: The Randomized PICSO-AMI-I Trial

Giovanni Luigi De Maria, MD

TRISCEND II

A Randomized Trial of Transcatheter Tricuspid Valve Replacement in Patients With Severe Tricuspid Regurgitation: The TRISCEND II Trial

Susheel K. Kodali, MD

TRILUMINATE

Quality of Life After Transcatheter Tricuspid-Valve Repair vs. Medical Therapy in Patients with Severe Tricuspid Regurgitation: Results from the Randomized TRILUMINATE Pivotal Trial

Suzanne V. Arnold, MD

VIVA

Transcatheter versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Small Aortic Annuli: A Randomized Clinical Trial (the VIVA Trial)

Josep Rodés-Cabau, MD

CLASP IID

One Year Outcomes from a Randomized Comparison of Transcatheter Edge-to-Edge Repair Systems For Degenerative MR: The CLASP IID Trial and Registry

Robert L. Smith, MD and Firas Zahr, MD

The Preliminary Program Guide can be found here: https://tct2023.crfconnect.com/program-guide. Media are invited to attend TCT and can apply for media credentials at: https://tct2023.crfconnect.com/press-registration.

Find more TCT23 conference coverage here